Canaccord Genuity analyst Max Masucci maintained a Buy rating on Natera (NASDAQ:NTRA) on Thursday, setting a price target of $125, which is approximately 10.35% above the present share price of $113.28.
Masucci expects Natera to post earnings per share (EPS) of -$0.72 for the first quarter of 2021.
The current consensus among 7 TipRanks analysts is for a Strong Buy rating of shares in Natera, with an average price target of $106.71.
The analysts price targets range from a high of $127 to a low of $87.
In its latest earnings report, released on 09/30/2020, the company reported a quarterly revenue of $98.14 million and a net profit of -$55.78 million. The company's market cap is $9.67 billion.
According to TipRanks.com, Canaccord Genuity analyst Max Masucci is currently ranked with 5 stars on a 0-5 stars ranking scale, with an average return of 85.6% and a 90.67% success rate.
Natera, Inc. engages in the discovery, development, and commercialization of genetic testing services. It offers Panorama Non-Invasive Prenatal Test, Horizon Carrier Screening, Spectrum Pre-implantation Genetic Screening and Spectrum Pre-implantation Genetic Diagnosis, Anora Products of Conception and Non-Invasive Paternity Testing. The company was founded by Matthew Rabinowitz and Jonathan Sheena in November 2003 and is headquartered in San Carlos, CA.